American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006
…, P Feyer, R Clark-Snow, JM Koeller… - Journal of clinical …, 2006 - ascopubs.org
Purpose To update the 1999 American Society of Clinical Oncology guideline for antiemetics
in oncology. Update Methodology The Update Committee completed a review and analysis …
in oncology. Update Methodology The Update Committee completed a review and analysis …
[PDF][PDF] Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines
…, DP Gill, S Groshen, S Grunberg, JM Koeller… - Journal of Clinical …, 1999 - Citeseer
THE GOAL OF ANTIEMETIC therapy is to prevent nausea and vomiting completely. This goal
is achieved for many patients receiving chemotherapy or radiation therapy, and is based …
is achieved for many patients receiving chemotherapy or radiation therapy, and is based …
Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy
…, LH Einhorn, S Grunberg, J Koeller… - Supportive Care in …, 2005 - Springer
This paper uses an evidence-based approach whenever possible to formulate recommendations,
emphasizing the results of controlled trials concerning the best use of antiemetic …
emphasizing the results of controlled trials concerning the best use of antiemetic …
Electrocardiographic and Cardiovascular Effects of the 5-Hydroxytryptamine3 Receptor Antagonists
RM Navari, JM Koeller - Annals of Pharmacotherapy, 2003 - journals.sagepub.com
OBJECTIVE: To review the electrocardiographic (ECG) and cardiovascular effects of 5-hydroxytryptamine
3 (5-HT 3 ) receptor antagonists preclinically, in healthy volunteers, and in …
3 (5-HT 3 ) receptor antagonists preclinically, in healthy volunteers, and in …
Fenofibrate-associated nephrotoxicity: a review of current evidence
…, CR Frei, L Ryan, JIM Koeller… - American journal of …, 2013 - academic.oup.com
Purpose The literature describing fenofibrate-associated nephrotoxicity was reviewed.
Summary Fenofibrate-associated nephrotoxicity is an underrecognized adverse effect that is …
Summary Fenofibrate-associated nephrotoxicity is an underrecognized adverse effect that is …
Proof of the quantum null energy condition
We prove the quantum null energy condition (QNEC), a lower bound on the stress tensor in
terms of the second variation in a null direction of the entropy of a region. The QNEC arose …
terms of the second variation in a null direction of the entropy of a region. The QNEC arose …
Cobalt (III)‐Catalyzed C H/N O Functionalizations: Isohypsic Access to Isoquinolines
CH/NO functionalizations by cobalt(III) catalysis allowed the expedient synthesis of a
broad range of isoquinolines. Thus, internal and challenging terminal alkynes proved to be …
broad range of isoquinolines. Thus, internal and challenging terminal alkynes proved to be …
Visible‐Light‐Enabled Ruthenium‐Catalyzed meta‐C−H Alkylation at Room Temperature
…, J Koeller, K Korvorapun, J Mohr… - Angewandte Chemie …, 2019 - Wiley Online Library
Visible‐light‐induced ruthenium catalysis has enabled remote C−H alkylations with excellent
levels of position control under exceedingly mild conditions at room temperature. The …
levels of position control under exceedingly mild conditions at room temperature. The …
Expedient C–H chalcogenation of indolines and indoles by positional-selective copper catalysis
P Gandeepan, J Koeller, L Ackermann - ACS Catalysis, 2017 - ACS Publications
A versatile protocol for the C–H chalcogenation of indolines and indoles by means of copper
catalysis was established. The C–H functionalization occurred selectively at the C7 position …
catalysis was established. The C–H functionalization occurred selectively at the C7 position …
Chemotherapy given near the end of life by community oncologists for advanced non-small cell lung cancer
JR Murillo Jr, J Koeller - The oncologist, 2006 - academic.oup.com
Purpose. To characterize the chemotherapy given near the end of life to advanced non-small
cell lung cancer (NSCLC) patients treated in the community oncology setting using a …
cell lung cancer (NSCLC) patients treated in the community oncology setting using a …